CGEN : Summary for Compugen Ltd. - Ordinary Shares - Yahoo Finance

U.S. Markets closed

Compugen Ltd. (CGEN)


NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
6.00+0.10 (+1.69%)
At close: 4:00 PM EST
People also watch:
CERSCRISCORTCAMTCYTK
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close5.90
Open6.00
Bid5.40 x 600
Ask6.90 x 1200
Day's Range6.00 - 6.10
52 Week Range4.32 - 7.57
Volume130,573
Avg. Volume120,022
Market Cap305.45M
Beta1.70
PE Ratio (TTM)-12.96
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswireyesterday

    Compugen Announces Key Highlights from R&D Day

    Disclosure of a therapeutic antibody program targeting TIGIT to complement the Company's CGEN-15029 program, following new data recently generated for the CGEN-15029/PVRIG program. Based on this and experimental data, the Company believes there is significant added value to developing both arms as a potential combination therapy. Compugen expects to select the lead antibody for CGEN-15137/TIGIT by end of Q1 2017.

  • PR Newswireyesterday

    Compugen Discloses its Cancer Immunotherapy Program Targeting TIGIT Immune Checkpoint

    Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, disclosed today CGEN-15137, its cancer immunotherapy program for TIGIT. TIGIT is an immune checkpoint in the B7/CD28 family which has recently gained broad industry interest in the field of immuno-oncology. At the recent Annual Meeting of the Society for Immunotherapy of Cancer, the Company disclosed data demonstrating that the CGEN-15029/PVRIG immune checkpoint, discovered by Compugen represents a new inhibitory component of the known TIGIT axis.

  • PR Newswire3 days ago

    Compugen Appoints Senior Vice President Corporate and Business Development

    Corporate & Business Development. Mr. Christoffersen, who will be based at Compugen's South San Francisco facilities, will report to Dr. Anat Cohen-Dayag, Compugen's President and Chief Executive Officer, and will have direct responsibility for the Company's business development strategy and its execution.